ArticleBritish journal of clinical pharmacology2021
Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios.
Article in British journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 6 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations.PharmacoEconomics - open · 2026Pooled it
- Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review.PharmacoEconomics · 2024Pooled it
- Cost-effectiveness of remdesivir for the treatment of hospitalized patients with COVID-19: a systematic review.Infectious diseases of poverty · 2023Pooled it
- Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review.Infection · 2023Pooled it
- Cost-effectiveness of interventions for the prevention and control of COVID-19: Systematic review of 85 modelling studies.Journal of global health · 2022Pooled it
- Diagnostics and Treatments of COVID-19: A Living Systematic Review of Economic Evaluations.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2022Pooled it
- COVID-19-related health utility values and changes in COVID-19 patients and the general population: a scoping review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Economic evaluation of strategies against coronavirus: a systematic review.Health economics review · 2023Review
- Incorporating productivity loss in health economic evaluations: a review of guidelines and practices worldwide for research agenda in China.BMJ global health · 2022Review
- An Analysis of Life-Year Lost Due to COVID-19 - 34 Countries, December 2019-March 2021.China CDC weekly · 2022Article
- The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2022Article
- Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios.British journal of clinical pharmacology · 2021Article
- Incorporating future unrelated medical costs in cost-effectiveness analysis in China.BMJ global health · 2021Article
- Remdesivir cost effective for severe COVID-19 in China.PharmacoEconomics & outcomes news · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe present study aimed to evaluate the cost-effectiveness of the 5-day remdesivir regimen compared with standard of care among severe COVID-19 patients in China, the evidence on which is essential to inform the necessity of securing access to remdesivir.
methodsA dynamic transmission model that extended the susceptible-exposed-infected-recovered framework by incorporating asymptomatic, presymptomatic and waiting-to-be-diagnosed patients was constructed to conduct the cost-effectiveness analysis from the healthcare system perspective. To estimate epidemic parameters, the model was first calibrated to the observed epidemic curve in Wuhan from 23 January to 19 March 2020. Following the calibration, the infected compartment was replaced by 3 severity-defined health states to reflect differential costs and quality of life associated with disease gravity. Costs and quality-adjusted life year (QALY) outcomes of 9 million simulated people were accrued across time to evaluate the incremental cost-effectiveness ratio of remdesivir. As robustness checks, an alternative modelling technique using decision tree, additional epidemic scenarios representing different epidemic intensities, and 1-way parameter variations were also analysed.
resultsRemdesivir treatment cost CN¥97.93 million more than standard of care. Also, the net QALY gain from 5-day remdesivir treatment was 6947 QALYs. As such, the incremental cost-effectiveness ratio was CN¥14 098/QALY, substantially lower than the gross domestic product per capita threshold. The peak daily number of severe cases was 19% lower in the remdesivir treatment strategy. Overall, results were robust in alternative scenarios and sensitivity analyses.
conclusionGiven the cost-effectiveness profile, access to remdesivir for severe COVID-19 patients in China should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.